BridgeBio Oncology Therapeutics COO Idan Elmelech's Tax Withholding Stock Transaction

This Form 4 filing reports that Idan Elmelech, COO & Principal Financial Officer of BridgeBio Oncology Therapeutics, Inc. (BBOT), had 343 shares of common stock withheld by the company on July 1, 2026, to satisfy tax withholding obligations related to the vesting of restricted stock units. The shares were withheld at a price of $7.80 per share, resulting in a total value of $2,675.40. Following this transaction, Elmelech retains 14,495 shares of common stock. The filing was signed by attorney-in-fact Aaron Chan on July 6, 2026. This represents a routine tax withholding transaction rather than a discretionary sale by the executive, as the shares were automatically withheld by the company to cover tax liabilities arising from equity compensation vesting.